Olav Hellebø, who formally led the Norwegian oncology developer Clavis Pharma ASA, has been appointed chief executive officer of ReNeuron Group Plc which has a clinical-stage cell therapy development business. At Clavis, Mr Hellebø took the company’s lead cancer programme through Phase 3, as well as completed substantial fundraising and out-licensing deals for the business.
Prior to Clavis, the executive headed the global biologics business at UCB Pharma and was head of UK commercial operations at Novartis. Mr Hellebø has an MBA from the IESE Business School in Spain and a Bachelor of Business Administration from Hofstra University in the US.
Michael Hunt, the company’s CEO since July 2005, will remain on the company’s board of directors as chief financial officer.
ReNeuron announced the appointment on 8 September 2014.
Copyright 2014 Evernow Publishing Ltd